Threatened Miscarriage: Evidence-Based Status and Advances in Western Medical Treatments.
- 1Department of Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150000, People's Republic of China.
- 2Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150000, People's Republic of China.
- 3The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310053, People's Republic of China.
Abstract
Threatened miscarriage is one of the most common complications during pregnancy and is characterized by complex and highly heterogeneous etiologies. In recent years, with the emergence of high-quality randomized controlled trials and updates in evidence-based guidelines, the management of threatened miscarriage has gradually shifted from empirical pregnancy preservation to risk stratification and precision intervention. This review summarizes the current evidence base and recent advances in Western medical treatment for threatened miscarriage, based on the latest clinical guidelines, randomized controlled trials, systematic reviews, and meta-analyses. Particular emphasis is placed on progesterone therapy, antithrombotic treatment, hormonal regulation during pregnancy, immunomodulatory therapy, tocolysis, and nutritional support. Current evidence indicates that vaginal micronized progesterone provides clear benefits for women with early pregnancy bleeding and a history of miscarriage. In contrast, the use of low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA) should be strictly restricted to selected high-risk populations. Levothyroxine (LT4) and metformin may offer potential benefits in patients with specific endocrine abnormalities; however, evidence supporting their routine use remains limited. In addition, the long-term benefits of immunomodulatory and tocolytic therapies remain uncertain. Overall, the Western medical management of threatened miscarriage should be individualized based on underlying etiological mechanisms, clinical phenotypes, and evidence-based recommendations. Future studies integrating biomarkers and multi-omics approaches are warranted to advance precision phenotyping and personalized treatment strategies for threatened miscarriage.
Related
- A mismatch in wildfire impact reduction and ecological restoration in western U.S. fuel treatments
- Mixed evidence that protected areas slow declines of threatened plant species in Germany
- Flavoglycans: Evidence for Covalent Proanthocyanidin-Polysaccharide Linkages in Western Redcedar Bark.
- Smallholder farmers' preferences for public expenditure priorities to support maize productivity: evidence from a best–worst scaling experiment in western Kenya
- Genomic and oceanographic evidence of reef connectivity across the western and central Indian Ocean
BibTeX
@article{wang2026threatened,
title = {{Threatened Miscarriage: Evidence-Based Status and Advances in Western Medical Treatments.}},
author = {Yu Wang and Zhuwei Gao and Yu Yao and You Wu and Shan Jiang and Yuqi Duan and Jiahui Zhao and Xiaoke Wu and Jingshu Gao},
journal = {International journal of women's health},
year = {2026},
month = oct,
doi = {10.2147/ijwh.s638716},
url = {https://europepmc.org/article/MED/42953783},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Threatened Miscarriage: Evidence-Based Status and Advances in Western Medical Treatments.
AU - Yu Wang
AU - Zhuwei Gao
AU - Yu Yao
AU - You Wu
AU - Shan Jiang
AU - Yuqi Duan
AU - Jiahui Zhao
AU - Xiaoke Wu
AU - Jingshu Gao
PY - 2026
DA - 2026/10/24
JO - International journal of women's health
DO - 10.2147/ijwh.s638716
UR - https://europepmc.org/article/MED/42953783
AB - Threatened miscarriage is one of the most common complications during pregnancy and is characterized by complex and highly heterogeneous etiologies. In recent years, with the emergence of high-quality randomized controlled trials and updates in evidence-based guidelines, the management of threatened miscarriage has gradually shifted from empirical pregnancy preservation to risk stratification and precision intervention. This review summarizes the current evidence base and recent advances in Western medical treatment for threatened miscarriage, based on the latest clinical guidelines, randomized controlled trials, systematic reviews, and meta-analyses. Particular emphasis is placed on progesterone therapy, antithrombotic treatment, hormonal regulation during pregnancy, immunomodulatory therapy, tocolysis, and nutritional support. Current evidence indicates that vaginal micronized progesterone provides clear benefits for women with early pregnancy bleeding and a history of miscarriage. In contrast, the use of low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA) should be strictly restricted to selected high-risk populations. Levothyroxine (LT4) and metformin may offer potential benefits in patients with specific endocrine abnormalities; however, evidence supporting their routine use remains limited. In addition, the long-term benefits of immunomodulatory and tocolytic therapies remain uncertain. Overall, the Western medical management of threatened miscarriage should be individualized based on underlying etiological mechanisms, clinical phenotypes, and evidence-based recommendations. Future studies integrating biomarkers and multi-omics approaches are warranted to advance precision phenotyping and personalized treatment strategies for threatened miscarriage.
SN - 1179-1411
ER -